Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aquestive Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Aquestive Therapeutics, Inc.’s stock price such as:

• Aquestive Therapeutics, Inc.’s current stock price and volume
• Why Aquestive Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for AQST from analysts
• AQST’s stock price momentum as measured by its relative strength

About Aquestive Therapeutics, Inc. (AQST)

Before we jump into Aquestive Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company’s proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Want to learn more about Aquestive Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aquestive Therapeutics, Inc..

Aquestive Therapeutics, Inc.’s Stock Price as of Market Close

As of February 12, 2025, 4:00 PM, CST, Aquestive Therapeutics, Inc.’s stock price was $3.390.

Aquestive Therapeutics, Inc. is up 14.14% from its previous closing price of $2.970.

During the last market session, Aquestive Therapeutics, Inc.’s stock traded between $2.910 and $3.420. Currently, there are approximately 91.08 million shares outstanding for Aquestive Therapeutics, Inc..

Aquestive Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Aquestive Therapeutics, Inc. Stock Price History

Aquestive Therapeutics, Inc.’s (AQST) price is currently up 12.25% so far this month.

During the month of February, Aquestive Therapeutics, Inc.’s stock price has reached a high of $3.420 and a low of $2.870.

Over the last year, Aquestive Therapeutics, Inc. has hit prices as high as $6.230 and as low as $2.240. Year to date, Aquestive Therapeutics, Inc.’s stock is down 4.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aquestive Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of February 11, 2025,, no analysts have changed their rating of Aquestive Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Aquestive Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aquestive Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aquestive Therapeutics, Inc. (AQST) by visiting AAII Stock Evaluator.

Relative Price Strength of Aquestive Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 11, 2025, Aquestive Therapeutics, Inc. has a weighted four-quarter relative price strength of -6.74%, which translates to a Momentum Score of 34 and is considered to be Weak.

Want to learn more about how Aquestive Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aquestive Therapeutics, Inc. Stock Price: Bottom Line

As of February 12, 2025, Aquestive Therapeutics, Inc.’s stock price is $3.390, which is up 14.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aquestive Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.